1 Adjunctive Ketamine for Sedation in Critically III Mechanically Ventilated Patients: An Active-Controlled,

2 Pilot, Feasibility Clinical Trial

- 3 Marwa Amer PharmD, BCPS, BCCCP^{1,2*}, Khalid Maghrabi MD, FCCP, MRCP^{2,3}, Mohammed Bawazeer MD, FRCSC,
- 4 FACS³, Kamel Alshaikh MD³, Mohammad Shaban MD³, Muhammad Rizwan MD³, Rashid Amin PharmD, BCPS,
- 5 BCCCP¹, Edward De Vol⁴, Mawadah Baali⁴, Malak Altewerki MD⁵, Mehreen Bano RN⁶, Fawziah Alkhaldi RN⁶,
- 6 Sanaa Alenazi RN⁶, Mohammed Hijazi MD, FCCP³
- 7 ¹Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- 8 ² College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- ³ Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- ⁴ Biostatistics, Epidemiology & Scientific Computing Department, King Faisal Specialist Hospital and Research
- 11 Center, Riyadh, Saudi Arabia
- ⁵ Department of Neurosciences, Residency Training Program, King Faisal Specialist Hospital and Research Center,
- 13 Riyadh, Saudi Arabia
- ⁶ Departments of Oncology Liver Nursing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi
- 15 Arabia
- 16 *Corresponding authors and address for reprints: Marwa Amer PharmD, BCPS, BCCCP, Critical Care Clinical
- 17 Pharmacy Consultant and Adjunct Assistant Professor- Alfaisal University- College of Medicine
- 18 King Faisal Specialist Hospital & Research Center, Pharmaceutical Care Division
- 19 (MBC # 11), PO Box 3354, Riyadh, 11211, Kingdom of Saudi Arabia, Tel: +966114647272 Ext 70836 or 48030
- 20 Email address: mamer@kfshrc.edu.sa
- 21 Conflicts of Interest and Source of Funding: None declared
- 22 Keywords: ketamine, critical care, sedation, mechanical ventilation, standard of care, ATTAINMENT

23 Abstract

24	Objective : Ketamine has been shown to decrease sedative requirements in intensive care unit (ICU).
25	Randomized trials are limited on patient-centered outcomes. We designed this pilot clinical trial to evaluate
26	the feasibility of using ketamine as an adjunct analgosedative compared with standard of care (SOC) alone and
27	determine preliminary effect size on 28-day mechanical ventilation (MV) duration and ventilator-free days
28	(VFDs).
29	Design: Pilot, single-center, active-controlled, open-label, randomized clinical trial.
30	Setting: Medical, surgical, and transplant ICUs at King Faisal Specialist Hospital and Research Center, Saudi
31	Arabia.
32	Patients and Methods: Adult patients who were intubated within 24 hours, expected to require MV for the
33	next calendar day, and had institutional pain and sedation protocol initiated.
34	Intervention: Adjunct ketamine infusion 1-2 μ g/kg/min for 48 hours versus SOC.
35	Measurements and Main Results: Total of 83 patients (43 in SOC and 40 in ketamine) were included.
36	Demographics were balanced between groups. Median MV duration was 7 (interquartile range [IQR] 3-9.25
37	days) in ketamine and 5 (IQR 2-8 days) in SOC, p= 0.15. Median VFDs was 19 (IQR 0-24.75 days) in ketamine
38	and 19 (IQR 0-24 days) in the SOC (p=0.70). More patients attained goal RASS score at 24 and 48 hours in
39	ketamine (67.5% and 73.5%, respectively) compared with SOC (52.4% and 66.7%, respectively). Sedatives and
40	vasopressors cumulative doses, and hemodynamic changes were similar. ICU length-of-stay was 12.5 (IQR 6-
41	21.2 days) in ketamine, compared with 12 (IQR 5.5-23 days) in SOC, p=0.89. Consent and protocol adherence
42	rate were adequate. No serious adverse events were observed in either group.
43	Conclusions : Use of ketamine as an adjunct analgosedative agent appeared to be feasible and safe with no

44 negative impact on outcomes, including hemodynamics. The protocol of this pilot trial could be improved by

modifying ketamine dosing regimen. These findings provide a basis for future, adequately powered, multicenter trial to investigate its association with patient-centered outcomes further.

64 Background

Analgo-sedation or analgesia-first-sedation has gained popularity in recent years (1). This approach has 65 66 been developed to decrease sedative use, and facilitate mechanical ventilation (MV) weaning (2). Data on ideal 67 sedative in intensive care unit (ICU) for mechanically ventilated, and hemodynamically unstable patients are 68 limited. Ketamine has a favorable hemodynamic, analgesic, and adverse effect profile, making it attractive as an 69 analgosedative agent (3,4). It inhibits N-methyl-D-aspartate (NMDA) receptors and activates opioid μ - and κ -70 receptors (5). When compared with other sedatives, ketamine has fastest onset (within 30-40 sec) and 15 min 71 duration of action. Anesthetists have long used ketamine for acute and chronic pain, procedural sedation, and 72 rapid sequence intubation. It has also been used in postoperative pain control in surgical and trauma patients 73 [as part of multimodal opioid-sparing analgesia in enhanced recovery after surgery (ERAS)], status asthmatics, 74 status epilepticus, alcohol withdrawal, and agitation (6,7).

75 Ketamine does not appear to have potential side effects of nonsteroidal anti-inflammatory drugs or 76 opioids negative effects on μ receptors of gastrointestinal tract associated with ileus (8-10). Studies to control 77 acute pain in traumatic rib fractures of severely injured individuals at sub-anesthetic doses resulted in 78 reduction of pain scale score and morphine-equivalent dose (11,12). Its use has been extended during 79 coronavirus disease (COVID-19) pandemic due to a shortage of other sedatives to keep patients on MV 80 comfortable and synchronous (13,14). Ketamine has not been associated with chest wall rigidity precipitating 81 insufficient ventilation, which has occasionally been described with fentanyl [15]. Additionally, propofol and 82 dexmedetomidine associated-hypotension may necessitate vasopressor support which may exclude patients 83 from qualifying for COVID-19 antiviral medication (remdesivir), making ketamine an attractive alternative [16].

There is an increasing body of literature on use of ketamine infusion as an analgosedative agent at ICU to reduce sedative requirement and maintain patients within target sedation agitation scale goal (17-20). However, evidence provided in Pain, Agitation-Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) guideline supporting its use in mechanically ventilated patients was insufficient due to limited number of randomized controlled trials (RCTs) (1,21). Data on whether ketamine affects patient-centered outcomes and

its safety in RCTs, as compared with standard of care (SOC), are unclear. We evaluated the feasibility of an Analgo-sedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU patients (ATTAINMENT trial) compared to SOC alone, using a randomized trial design to determine preliminary estimates and effect size on patient-centered outcomes for future adequately powered clinical trial.

93 Patients and Methods:

94 This was an investigator-initiated, pilot, single-center, parallel-group, open-label RCT. The trial was registered 95 with ClinicalTrials.gov: NCT04075006, current controlled trials: ISRCTN14730035, and Saudi Food and Drug 96 Authority: SCTR #19063002. Our institution's research ethics committee approved the trial (number 2191 187). 97 Full study protocol has been published previously (22). The trial was conducted according to CONSORT 98 guidelines extension to randomized pilot and feasibility trials. Participants were recruited from King Faisal 99 Specialist Hospital and Research Center (KFSH&RC), Riyadh. It is a major referral center that provides tertiary 100 and quaternary care. The ICU department is composed of several ICUs (medical, surgical, and transplant). 101 During COVID-19 pandemic, new units were opened to accommodate patients surge.

102 <u>Study Population</u>

103 Patients were eligible for inclusion if they were admitted to any of our three adult ICUs, intubated within 104 previous 24-hours and expected to continue on MV the next calendar day, initiated on institutional pain and 105 sedation protocol, and no objection from ICU attending or primary treating team. Recruitment began in 106 September 2019 and was completed in November 2020. Patients were excluded if they had history of dementia 107 or psychiatric disorders, or were comatose on admission due to hepatic encephalopathy. Other exclusion 108 criteria were: severe pulmonary hypertension, tracheostomy at baseline, intellectual disability that precluded 109 delirium assessment, transfer from an external facility, history of substance abuse, and situations where high 110 blood pressure could trigger dangerous complications, such as aortic dissection. We also excluded those with 111 repeated ICU admissions within same hospital visit and those who participated in another interventional trial. 112 Full inclusion and exclusion criteria are detailed in **Supplementary Table 1**. Our research coordinators, along 113 with local principal investigators screened patients for eligibility by using an electronic screening form in

Research Electronic Data Capture (REDCap). Once eligibility criteria were met, informed consent was obtained.
Given the need to enroll patients in expedited manner within 24-hours window, verbal consent from surrogate
decision-maker (SDM) was allowed and documented in electronic medical records (EMR). Written consent was
obtained as soon as SDM became available.

118 Patients were randomized in a 1:1 allocation using a computer-generated, pre-determined randomization list created by an independent biostatistician; no stratification was performed. Group allocation was concealed 119 120 until after randomization. The investigators were masked to outcome data during the trial. Since this was an 121 open-label study and because of lack of funding, blinding of investigators and treating team was not possible at 122 this phase. However, patients and families were unaware of group assignment. Supplementary Figure 1A, 1B 123 summarized treatment algorithm. After randomization, control group (SOC) was started on KFSH&RC ICU 124 analgesia and sedation protocol. Since it was a nurse-driven protocol, treating team placed an order regarding 125 target Richmond Agitation-Sedation Scale (RASS), and sedatives infusions were adjusted according to RASS 126 target by bedside ICU nurse. For those randomized to intervention group (ketamine), continuous infusion 127 ketamine 1-2 µg/kg/min was added as an adjunct for 48-hours. The infusion could be weaned off earlier in 128 preparation for extubation. Since this was only a feasibility trial, there was no further intervention after 48-129 hours; however, clinical outcomes and adverse events (AEs) were monitored up to day 28. Ketamine dose was 130 reported in µg per kilogram of actual body weight per min as per institutional practice. Other aspects of care, 131 including fluid management, vasopressors use, blood products, enteral nutrition, renal replacement therapy, 132 and early mobilization at discretion of treating team, were similar in both groups. ICU supportive measures 133 were applied as appropriate, including venous thromboembolism prophylaxis, and prone positioning of 134 patients who met the criteria based on established guidelines for acute respiratory distress syndrome (ARDS). 135 Septic patients were managed according to latest survival sepsis campaign guidelines. Patient-ventilator 136 asynchrony was systematically assessed and managed through inter-professional collaboration by prioritizing 137 analgesia, and management of MV to avoid unnecessary use of neuromuscular blocking blockers [NMB]. 138 Spontaneous awakening trial (SAT) was assessed every morning with SAT safety screen unless patients were

receiving sedative infusion for status epilepticus or started on NMB post-randomization. Patients who passed SAT were immediately managed using spontaneous breathing trial (SBT) protocol. Both groups received basic analgesic regimen that included paracetamol and epidural analgesia for hyperthermic intraperitoneal chemotherapy (HIPEC) patients. If delirium treatment was needed, non-pharmacological measures (reassurance or mobilization, and family support) were applied first. If this was insufficient, the protocol allowed the use of antipsychotics and decision was left to ICU physician.

145 Outcome Variables

Primary outcome was median duration of MV, with ventilator-free days (VFDs) up to day 28 as co-primary 146 147 outcome. This outcome was chosen as patient-centered and highly influenced by mortality (23). Secondary 148 outcomes included the following up to 28 days: ICU and hospital length-of-stay (LOS), mortality rate, and 149 percentage of participants with AEs. We collected proportion and daily cumulative dose of vasopressors, 150 sedatives and analgesics [fentanyl, propofol, midazolam, and dexmedetomidine], and antipsychotics over 48-151 hours post-randomization. Data on sedatives administered outside ICU settings during anesthesia or 152 intraoperative management were not collected. Presence of delirium was assessed using confusion assessment 153 method for ICU (CAM-ICU), which was measured at baseline and 48-hours post-randomization. If CAM-ICU 154 scores were not available, an electronic progress note was reviewed to detect any evidence of delirium. 155 Hemodynamic parameters [heart rate and mean arterial pressure (MAP)] were collected 48-hours post-156 randomization. Hemodynamic changes were defined as presence of tachycardia, hypertension, and 157 hypotension. Details about variables collected and their definitions are available in Supplementary File 1, and 158 Supplementary Table 2. Data were stored online in REDCap web application and data quality assessments were 159 executed routinely to ensure completion and accuracy. Feasibility was assessed by evaluating consent rate, 160 recruitment success, and protocol adherence. Consent rate was deemed to be adequate if > 70% of SDMs or 161 patients chose to participate upon being approached. Successful recruitment was defined as > 3 patients 162 enrolled per month. Protocol adherence was defined as >75% of patients receiving ketamine according to 163 prescribed protocol. These thresholds were chosen after examining other pilot studies on complex

interventions (22). We conducted educational sessions for clinicians, nurses, and hospital pharmacies to facilitate implementation of protocol. Protocol deviation was defined as not starting ketamine immediately after randomization (ideally within 4-hours) due to pharmacy delay or non-placement of ketamine order.

167 <u>Statistical analysis</u>

168 Overall study population included all patients who were enrolled, randomly assigned, and received at least one 169 dose of study medication, constituting modified intention-to-treat (mITT) population. Statistician was blinded 170 to study group allocation and performed statistical analyses using R statistical software Version 3.5.0 (R 171 Foundation for Statistical Computing, Vienna, Austria) and SAS/JMP version 15.0 (SAS Institute, Cary, NC). 172 Counts and percentages were used to summarize distribution of categorical variables. Continuous variables 173 were summarized using either mean ± standard deviation or median and interquartile range (IQR), based on 174 results of normality testing (using Shapiro-Wilk test and Histograms). Chi-square test of independence was used 175 to assess whether distribution of categorical variables was different between groups. Unpaired t-test or Mann-176 Whitney test was used to compare distribution of normal and non-normal continuous variables. Variables with 177 more than one possible response were dummy coded, and percentage of each response was calculated from 178 total sample size. VFDs were calculated by subtracting number of ventilation days from 28 after assigning 179 VFD=0 for patients who died during 28 days. Sensitivity analysis for sedative and vasopressor requirements, 180 excluding patients started on NBM post-randomization, was conducted. We ensured immediate data entry and 181 identified missing data quickly, and issues were resolved promptly. Thus, no imputation for missing variables 182 was done. Since this is a pilot and feasibility trial, there was no formal sample size calculation. A convenient 183 sample of about 40 patients per group was thought to be roughly sufficient for this pilot trial (24).

184 **Results**

From September 2019 through November 2020, a total of 437 MV patients were screened; 83 patients met inclusion criteria and 354 were excluded. Among screened patients, 88 did not meet eligibility criteria, mainly because they were expected to require MV for < 24-hours. Among included patients, 43 were in SOC group and 40 were included in ketamine group in mITT analysis. Participants' flow through the trial is shown in **Figure 1**.

189 Other exclusion criteria assessed were pulmonary hypertension (3 patients), tracheostomy at baseline post-

190 face flab or due to subglottic stenosis (11 patients), intellectual disability that precluded delirium assessment (2

191 patients), transferred from outside facility (2 patients), and history of substance abuse (3 patients).

192 Baseline demographics are described in Table 1 and Supplementary Table 3. Median age was 60 years, with a 193 higher proportion of males. About half of the patients were from medical ICU, 26.5% from surgical ICU, and 194 25.3% from transplant ICU; median SOFA 8, and APACHE II 20. Overall, demographic characteristics were 195 balanced between groups in terms of sex, race, and comorbidities, except for prevalence of chronic obstructive 196 pulmonary disease, which was higher in SOC group. We included a wide variety of ICU admission diagnoses and 197 among those randomized to ketamine, 60% had ARDS and about 34% were recipients of solid organ transplants 198 or had solid malignancy. Other primary reasons for ICU admission included HIPEC (3 patients: 2 in ketamine and 199 1 in SOC), COVID-19 pneumonia (2 patients: one in each group), and sickle cell disease (1 patient in ketamine). 200 Ketamine-treated patients were noted to have higher median lactate level (2.2 [IQR 1.58-3.4 mmol/L] p= 201 0.004). Median number of hours of ICU admission before study enrollment was 13 (IQR 6-21.15) in SOC and 15 202 (IQR 12-21) in ketamine (p=0.17). Post randomization, NMB was initiated in 12.5% of ketamine-treated patients 203 compared to 4.65% in SOC.

Patients outcomes are summarized in **Table 2.** Median duration of MV on day 28 was 7 days in ketamine group (IQR 3-9.25) compared to 5 days in SOC group (IQR 2-8). Among the 83 patients assessed, a similar proportion of patients had been weaned off MV at 28 days: 25 of 40 (62.5%) in ketamine group and 27 of 43 (62.8%) in SOC. Median distribution of VFDs at day 28 was 19 days in both groups (P = 0.70). Median duration of ICU LOS was comparable between groups. More patients in ketamine achieved goal RASS at 24 and 48 hours (67.5% and 73.5%, respectively) compared to SOC (52.4% and 66.7%, respectively). Additional details on outcomes are available in **Supplementary Table 4, Supplementary Figure 2.**

Safety outcomes are described in **Table 3**. Proportion of patients who did not complete 48-hours of the trial was higher in ketamine (37.5%) than in SOC (11.63%) and the main reason was weaning off sedation in

213 preparation for extubation. Antipsychotics were started in 3 ketamine-treated patients compared to 4 patients in SOC (p=1). Dexmedetomidine initiation within 48-hours post-randomization was similar between groups. 214 215 Higher frequency of hypersalivation and frequent suctioning was observed in SOC arm. Regarding 216 hemodynamic changes in HR and MAP at 24 and 48-hours, we found no difference between groups (Figure 2). 217 The 28-day mortality rate was 11 (27.5%) in ketamine compared with 14 (32.6%) in SOC, p= 0.79. Data Safety Monitoring Committee reviewed all deaths, and all were determined to have been due to underlying disease, 218 219 with participation in trial not being a contributing factor. More details of safety outcomes are available in 220 Supplementary Table 5.

Supplementary Tables 6-7, Supplementary Figures 3-4 described sedative and vasopressor requirements. 221 222 Median RASS was -2 at baseline, which gradually increased to -1 during 48-hours post-randomization, indicating 223 light sedation and ability of patients to make eye contact with verbal stimulation. Thirty-six patients underwent 224 CAM-ICU assessment within 48-hours post-randomization (43.37 %), of which 2 were positive in ketamine 225 group (5%). There was no difference in baseline values of vasopressor and sedative requirements pre-226 randomization, except for amount of vasopressin which was higher in ketamine-treated patients (median 39.6, 227 IQR 30.5-64.2 units, P = 0.053). Cumulative doses of fentanyl and other sedatives were similar between two 228 groups at 48-hours post-randomization. Similar trends were observed for cumulative vasopressors dose in mg 229 at 48-hours post-randomization. Sensitivity analysis was conducted on sedative requirements, excluding those 230 started on NMB post-randomization, and findings were consistent with primary analysis.

Regarding feasibility outcomes, average patients enrollment was 3-4 patients/month. Consent rate was adequate; > 70% of SDMs or patients choosing to participate when approached for consent. Recruitment rate decreased significantly during COVID-19 pandemic and was halted for 1 month. We resumed recruitment at a slower rate in March 2020, with an average of 1-2 patients/month. In total, 12% of patients were enrolled outside traditional working hours (on weekends or night shifts). This process was facilitated through close collaboration with on-call ICU physician. Protocol adherence was 97.5% and median hours from consent or enrollment until ketamine started was 4.25 [IQR 2.08-5.88]. Adherence rate was lower than expected (90%)

during COVID-19 pandemic. We were able to improve compliance using strategies such as education sessions

239 for research and clinical staff and routine clinical reminders, including documentation in EMR.

240 Discussion

241 This pilot proved the feasibility of a clinical trial to evaluate the use of ketamine as an analgosedative in 242 ICU patients with MV. Achieving our threshold of recruitment and consent rate demonstrated that the trial is 243 acceptable to clinicians, patients, and families. Major barriers faced were difficulties in continuing under 244 lockdown conditions, infected research staff, shifting staff to cover COVID-19 ICU, and reorientation in clinical 245 trial research towards COVID-19. We demonstrated that ketamine appeared to be safe, and majority of the patients achieved target RASS and pain scores. There was no increase in antipsychotics or dexmedetomidine 246 247 use post-randomization and no notable hemodynamics changes. As this was a pilot study, it was not powered 248 to detect statistically significant differences in patient-centered outcomes between the two groups.

249 Most previous studies had a limited focus on patient-centered outcomes as primary outcome favoring 250 surrogate outcomes, such as sedation scores and changes in analgesics and sedatives, leaving a significant 251 knowledge gap about the use of ketamine as a sedative agent in ICU. To the best of our knowledge, this pilot 252 trial was the first that reported a patient-centered outcome as primary outcome and included diverse ICU 253 population. We chose duration of MV as a primary outcome, because ketamine lowers airway resistance, 254 preserves pharyngeal and laryngeal protective reflexes, increases lung compliance, and is less likely to cause 255 respiratory depression in low and slow infusions (4). Median duration of MV and VFDs in our cohort was 256 consistent with that reported in MENDS2 sedation trial; adjusted median, 23.7 days in dexmedetomidine vs. 24 257 days in propofol; OR, 0.96; 95% CI, 0.74-1.26) (25). It is noteworthy that majority of our population were from 258 medical ICU (48.2% of entire cohort) and had moderate ARDS, with a median baseline PaO2/FiO2 ratio of 152. 259 Patients with ARDS may be under-represented in analgesia/sedation studies and currently recommended 260 ketamine dosing strategy in this pilot may not be feasible and could be improved by modifying the regimen in 261 upcoming adequately powered, multicenter trial.

262 In this pilot trial, cumulative doses of fentanyl and other sedatives were similar between the two arms. 263 This could be explained by the fact that proportion of patients who did not complete 48-hours of the trials was 264 significantly different between groups and was higher in ketamine group (37.5%). This could also be due to 265 starting NMB in five patients randomized to ketamine compared to two patients in SOC after randomization. In 266 addition, protocol adherence rate and sedatives titration were lower than expected (90%) during COVID-19 267 pandemic, possibly due to re-assignment of ICU nurses to COVID-19 ICUs. Subsequently, newly hired non-ICU 268 nurses were assigned to cover manpower shortages in non-COVID-19 ICUs and could be unaware of study 269 protocol. Hence, efforts to reduce concomitant sedatives with ketamine may be conservative. A trial by Guillou 270 et al which showed a reduction in opioid consumption with low-dose ketamine infusion for 48-hours (26). 271 However, patients in this trial underwent postoperative abdominal surgery and were able to use patient-272 controlled analgesia. It is difficult to extrapolate these findings to mechanically ventilated patients who are 273 unable to self-report pain and have a higher severity of illness as in our cohort.

274 Another question to address pertains to ketamine dosing for analgosedation. It is well known that 275 severity of critical illness influences drug pharmacokinetics and pharmacodynamics (27). Hemodynamic 276 instability, sympathetic overstimulation, and acute septic brain dysfunction negatively affect organ function 277 and thus distribution, absorption, metabolism, and drug dose-response relationships. Severely ill patients need 278 much lower doses of sedatives to maintain adequate sedation. Ketamine is highly lipophilic and is metabolized 279 in liver, generating active compounds (norketamine and hydroxynorketamine), and is eliminated in urine with 280 an elimination half-life of 1.5-3 hours (28,29). Published data for ketamine doses showed that it can be safely 281 titrated up to 10-20 µg/kg/min, as needed, to achieve desired level of analgosedation. We chose ketamine 282 dosing at 1-2 µg/kg/min, because majority of ICU population included in our pilot were older (median age 61 283 years), with renal and hepatic dysfunction, which potentially alters metabolism and excretion of ketamine and 284 its active metabolite, resulting in increased sensitivity to ketamine, prolonged duration, drug accumulation, and 285 possible longer recovery. Moreover, the dose described in this pilot was in agreement with existing literature 286 describing light sedation strategy and 2018 PADIS guideline recommendations (1,13). This regimen is more

conservative, to minimize dose-related reactions, such as psychotomimetic side effects, which could lead to complex differential diagnoses in ICU patients who are prone to delirium and other CNS disturbances. We also did not observe notable severe confusion, nightmares, emergence phenomena, or serious AEs associated with ketamine use, which is consistent with the findings reported by Perbert *et al* (30).

291 Ketamine has a sympathomimetic effect and can cause hypertension and tachycardia by acting as a 292 catecholamine re-uptake inhibitor. However, in a subgroup of patients, particularly those with a 293 catecholamine-depleted state, it can sometimes cause hemodynamic compromise and hypotension (31). It is 294 recommended to be avoided in patients with a history of cardiac disease or hypertensive crisis, due to its 295 myocardial depressant effect (32). In our pilot trial, we excluded patients with cardiogenic shock due to 296 potential harm. Moreover, ketamine was not associated with clinically significant hemodynamic changes and 297 appeared to be safe. There was no increase in vasopressor requirements post-randomization despite the fact 298 that ketamine-treated patients were sicker at baseline, as evident by higher lactate level and higher 299 vasopressin dose at baseline.

We noticed that 28-day mortality rate in our cohort was 30.1% (32.6% in SOC and 27.5% in ketamine), which was slightly higher than mortality rate reported in older sedation trials (MIDEX and PRODEX trial) (33). This was expected because we are a tertiary care hospital. APACHE II and SOFA scores also suggest that these data were derived from a cohort of critically ill patients. This is comparable to mortality rate in patients admitted to ICU with severe sepsis and shock and to all-cause mortality rate reported in more recent sedation trials, such as SPICE III trial (29.1% in both dexmedetomidine and usual-care groups) and MENDS2 trial (38% in dexmedetomidine group vs. 39% in propofol, HR, 1.06; 95% CI, 0.74 -1.52) (25,34,35).

This pilot trial had several strengths. Firstly, it included patient-centered outcomes, high rates of completed follow-up, and comprehensive assessments of AEs associated with ketamine use and its impact on hemodynamic response. We believe that our results provide incremental value in understanding the effects of ketamine. Adherence to mITT principle, randomization, and blinded outcome assessors limited potential sources of bias. Moreover, our trial included diverse ICU populations from medical, surgical, and transplant

312 ICUs. We also made every effort to include eligible patients within a narrow randomization window (within 24-313 hours of intubation) to eliminate potential confounders with other co-interventions. Lastly, study protocol 314 (design, study enrollment, and outcomes) aligns with the design of clinical trials evaluating sedation in critically 315 ill adult MV patients (36).

316 We acknowledge limitations of our pilot trial. It was a single-center and did not include neurocritical care ICU patients, such as those with severe traumatic brain injury (TBI) and hydrocephalus. More recent 317 318 systematic reviews of mixed acute brain populations (subarachnoid hemorrhage, tumors, and TBI) concluded 319 that ketamine had no detrimental effect on intracranial pressure, ICU LOS, or mortality (37). Furthermore, we 320 did not collect data on frequency and duration of prone positioning for ARDS patients who were made prone, 321 or median change in PaO2/FiO2 ratio post-randomization, limiting the ability to determine the real benefit of 322 ketamine in oxygenation post-randomization. Although we made efforts to validate the diagnosis of delirium 323 and delirium assessment with CAM-ICU, we had a large proportion of patients (56.6 %) with un-assessed CAM-324 ICU, leaving a knowledge gap to be addressed in future trial. Finally, ketamine duration was limited to 48-hours 325 due to the nature of this pilot trial and longer duration needs to be investigated in future. We believe that the 326 trial protocol could be improved by modifying the current ketamine dosing regimen, capturing MV settings 327 after randomization, and collecting data on other co-interventions (e.g. corticosteroids, prone positioning, and 328 diuretics). Future trial may also consider looking at ketamine analgo-sedative effect in COVID-19 and 329 neurocritical care ICUs. Finally, ketamine is not an expensive drug. Currently, no studies have evaluated cost-330 effectiveness of ketamine in management of sedation and analgesia and this should be considered in future.

331 Conclusions

332 Ketamine is potentially attractive option for analgosedation. In our pilot trial, ketamine appeared to be 333 safe, and feasible with no negative impact on outcomes, including hemodynamics. However, this pilot trial is 334 not sufficiently powered to show a difference in clinical outcomes. While these data are encouraging, results 335 generated from this pilot lay the foundation for a future adequately powered, multicenter trial to shed light on 336 remaining questions and investigate the association with patient-centered outcomes further.

14

338 Availability of data and material

- 339 The datasets used and analyzed during the current report are available from the corresponding author on
- 340 reasonable request.

341 Acknowledgments

- 342 We thank the ICU physicians, ICU nurses, ICU respiratory therapists, ICU physiotherapists, ICU satellite
- 343 pharmacists, and ICU clinical pharmacists of KFSH&RC for their efforts to save the lives of ICU patients and
- their bravery in fighting against the COVID-19 pandemic. We also thank the Saudi Critical Care Trials Group
- 345 for providing feedback on the study proposal, as well as participants and their families. Without their
- 346 collective generosity, this trial would not have been possible.

362	Figures legends
363	Figure 1: Study Flow Chart
364	¶ deemed to be extubatable post-randomization
365	Abbreviations: ESLD, end-stage liver diseases; HR, heart rate; SBP, systolic blood pressure; ECMO,
366	extracorporeal membrane oxygenation; DNR, do-not-resuscitate
367	
368	Figure 2. HR and MAP at baseline, 24 hours, and 48 hours
369	Abbreviation: SOC, standard of care; HR, heart rate; MAP, mean arterial pressure
370	
371	
372	
373	
374	
375	
376	
377	
378	
379	
380	
381	
382	
383	
384	
385	
386	

387 References

- 388 1. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al: Clinical practice
- 389 guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep
- disruption in adult patients in the ICU. *Crit Care Med* 2018; 46:e825-e873.
- 391 2. Shah FA, Girard TD, Yende S: Limiting sedation for patients with acute respiratory distress syndrome—
- 392 Time to wake up. *Curr Opin Crit Care* 2017; 23:45-51.
- 393 3. Whitman CB, Rhodes H, Tellor BR, Hampton NB: Continuous infusion of ketamine for adjunctive
- 394 sedation in medical intensive care unit: A case series. J Anesthesiol Crit Care Medi 2015; 2:1-5.
- 395 4. Wieruszewski PM, Leung JG, Nelson S: Ketamine Use in the Intensive Care Unit. AACN Adv Crit Care

396 2018; 29: 101-106.

- 397 5. Hanidziar D, Bittner EA: Sedation of mechanically ventilated COVID-19 patients: Challenges and special
- 398 considerations. Anesth Analg 2020; 13:e40-e41.
- 399 6. Hurth KP, Jaworski A, Thomas KB, Kirsch WB, Rudoni MA, Wohlfarth KM: The reemergence of ketamine
- 400 for treatment in critically ill adults. *Crit Care Med* 2020; 48:899-911.
- 401 7. Radvansky BM, Shah K, Parikh A, Sifonios AN, Le V, Eloy JD: Role of ketamine in acute postoperative pain
- 402 management: a narrative review. *Biomed Res Int* 2015; 2015:749837.
- 403 8. Joachimsson PO, Hedstrand U, Eklund A: Low-dose ketamine infusion for analgesia during postoperative
- 404 ventilator treatment. *Acta Anaesthesiol Scand* 1986; 30:697-702.
- 405 9. Takieddine SC, Droege CA, Ernst N, Droege ME, Webb M, Branson RD, et al: Ketamine versus
- 406 hydromorphone patient-controlled analgesia for acute pain in trauma patients. *J Surg Res* 2018; 225:6-14.
- 407 10. Zhao H, Yang S, Wang H, Zhang H, An Y: Non-opioid analgesics as adjuvants to opioid for pain
- 408 management in adult patients in the ICU: A systematic review and meta-analysis. J Crit Care 2019;54:136-144.
- 409 11. Kugler NW, Carver TW, Juul J, Peppard WJ, Boyle K, Drescher KM, et al: Ketamine infusion for pain
- 410 control in elderly patients with multiple rib fractures: Results of a randomized controlled trial. J Trauma Acute
- 411 Care Surg. 2019;87(5):1181-8.

- 412 12. Carver TW, Kugler NW, Juul J, Peppard WJ, Drescher KM, Somberg LB, et al. Ketamine infusion for pain
- 413 control in adult patients with multiple rib fractures: Results of a randomized control trial. J Trauma Acute
- 414 *Care Surg* 2019; 86:181-188.
- 415 13. Chanques G, Constantin JM, Devlin JW, Ely EW, Fraser GL, Gélinas C, et al: Analgesia and sedation in
- 416 patients with ARDS. Intensive Care Med 2020; 46:2342-2356.
- 417 14. Adams CD, Altshuler J, Barlow BL, Dixit D, Droege CA, Effendi MK, et al: Analgesia and sedation strategies
- in mechanically ventilated adults with COVID-19. *Pharmacotherapy* 2020; 40:1180-1191.
- 419 15. Phua CK, Wee A, Lim A, Abisheganaden J, Verma A: Fentanyl-induced chest wall rigidity syndrome in a
- 420 routine bronchoscopy. *Respir Med Case Rep* 2017; 20:205-207
- 421 16. Ammar MA, Sacha GL, Welch SC, Bass SN, Kane-Gill SL, Duggal A, et al: Sedation, analgesia, and paralysis
- 422 in COVID-19 patients in the setting of drug shortages. J Intensive Care Med 2021; 36:157-174.
- 423 17. Erstad BL, Patanwala AE. Ketamine for analgosedation in critically ill patients. J Crit Care 2016; 35:145-
- 424 149
- 425 18. Groetzinger LM, Rivosecchi RM, Bain W, Bahr M, Chin K, McVerry BJ, et al: Ketamine infusion for adjunct
- 426 sedation in mechanically ventilated patients. *Pharmacotherapy* 2018; 38:181-188.
- 427 19. Garber PM, Droege CA, Carter KE, Harger NJ, Mueller EW: Continuous infusion ketamine for adjunctive
- 428 analgosedation in mechanically ventilated, critically ill patients. *Pharmacotherapy* 2019; 39:288-296.
- 429 20. Pruskowski KA, Harbourt K, Pajoumand M, Chui SJ, Reynnolds HN: Impact of ketamine use on adjunctive
- 430 analgesic and sedative medications in critically ill trauma patients. *Pharmacotherapy* 2017; 37:1537-1544.
- 431 21. Bawazeer M, Amer M, Maghrabi K, Al-Sheikh K, Amin R, Rizwan M, et al: Adjunctive continuous
- 432 ketamine infusion to conventional sedation in mechanically ventilated patients: It is time for a randomized
- 433 trial. Saudi Crit Care J 2020; 4:5-8.
- 434 22. Bawazeer M, Amer M, Maghrabi K, Alshaikh K, Amin R, Rizwan M, et al: Adjunct low-dose ketamine
- 435 infusion vs standard of care in mechanically ventilated critically ill patients at a Tertiary Saudi Hospital
- 436 (ATTAINMENT Trial): Study protocol for a randomized, prospective, pilot, feasibility trial. Trials 2020; 21:288.

437 23. Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW: Reappraisal of ventilator-free days in

- 438 critical care research. Am J Respir Crit Care Med 2019; 200:828-836
- 439 24. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good
- 440 practice. J Eval Clin Pract. 2004 May;10(2):307-12.

441 25. Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, et al: Dexmedetomidine or

- 442 propofol for sedation in mechanically ventilated adults with sepsis. *N Engl J Med* 2021.
- 443 26. Guillou N, Tanguy M, Seguin P, Branger B, Campion J, Mallédant Y: The effects of small-dose ketamine
- 444 on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth
- 445 Analg 2003; 97:843-847.
- 446 27. Power BM, Forbes AM, van Heerden PV, Ilett KF: Pharmacokinetics of drugs used in critically ill adults.
- 447 *Clin Pharmacokinet* 1998; 34:25-56.
- 28. Opdenakker O, Vanstraelen A, De Sloovere V, Meyfroidt G: Sedatives in neurocritical care: an update on
 pharmacological agents and modes of sedation. *Curr Opin Crit Care* 2019; 25:97-104.
- 450 29. Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al: Ketamine and ketamine
- 451 metabolite pharmacology: insights into therapeutic mechanisms. *Pharmacol Rev* 2018; 70:621-660.
- 452 30. Perbet S, Verdonk F, Godet T, Jabaudon M, Chartier C, Cayot S, et al: Low doses of ketamine reduce
- 453 delirium but not opiate consumption in mechanically ventilated and sedated ICU patients: A randomised

454 double-blind control trial. *Anaesth Crit Care Pain Med* 2018; 37:589-595.

- 455 31. Miller M, Kruit N, Heldreich C, Ware S, Habig K, Reid C, et al: Hemodynamic response after rapid
- 456 sequence induction with ketamine in out-of-hospital patients at risk of shock as defined by the shock index.
- 457 Ann Emerg Med 2016; 68:181-188.e2.
- 458 32. Christ G, Mundigler G, Merhaut C, Zehetgruber M, Kratochwill C, Heinz G, et al: Adverse cardiovascular
- 459 effects of ketamine infusion in patients with catecholamine-dependent heart failure. Anaesth Intensive Care
- 460 1997; 25:255-259.

- 461 33. Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al: Dexmedetomidine vs
- 462 midazolam or propofol for sedation during prolonged mechanical ventilation: Two randomized controlled
- 463 trials. JAMA 2012; 307:1151–1160.
- 464 34. Vallet H, Schwarz GL, Flaatten H, de Lange DW, Guidet B, Dechartres A: Mortality of older patients
- admitted to an ICU: A systematic review. *Crit Care Med* 2021; 49:324-334.
- 466 35. Shehabi Y, Howe BD, Bellomo R, Arabi YM, Bailey M, Bass FE, et al. Early sedation with
- 467 dexmedetomidine in critically ill patients (SPICE III). *N Engl J Med* 2019; 380:2506-2517.
- 468 36. Ward, Denham S; Absalom, Anthony R; Aitken, Leanne M. et al: Design of clinical trials evaluating
- sedation in critically ill adults undergoing mechanical ventilation. *Critical Care Med* 2021.
- 470 37. Gregers MCT, Mikkelsen S, Lindvig KP, Brøchner AC: Ketamine as an anesthetic for patients with acute
- 471 brain injury: a systematic review. *Neurocrit Care* 2020; 33:273-282.

472

473

474

475

476





Figure 2. HR and MAP at baseline, 24 hours, and 48 hours

Table 1.Demographic and baseline characteristics

	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
Age, years	61 (44.5-71)	61 (47.5-70)	59 (40.5-73)	0.61
Male, N (%)	51 (61.4)	25 (58.1)	26 (65.0)	0.68
Weight, kilogram	65 (50.7-73.2)	61.8 (47.5-69.4)	67.5 (51.9-81.2)	0.09
ICU type, N (%)				0.74
Medical	40 (48.2)	19 (44.2)	21 (52.5)	
Surgical	22 (26.5)	12 (27.9)	10 (25)	
Transplant ICU	21 (25.3)	12 (27.9)	9 (22.5)	
The primary reason for ICU admission, N (%)				
Sepsis or septic shock	25 (30.1)	14 (32.6)	11 (27.5)	0.79
Acute respiratory distress syndrome	50 (60.2)	28 (65.1)	22 (55)	0.47
Cardiovascular	8 (9.64)	3 (6.98)	5 (12.5)	0.47
Gastrointestinal	6 (7.23)	5 (11.6)	1 (2.5)	0.20
Neurological	10 (12)	5 (11.6)	5 (12.5)	1
Trauma	2 (2.41)	1 (2.33)	1 (2.5)	1
Comorbidities, N (%)				
COPD	6 (7.23)	6 (14)	0 (0)	0.03
Mild liver dysfunction [Child Pugh score A, B]	9 (10.8)	6 (14)	3 (7.5)	0.49
Diabetes	28 (33.7)	17 (39.5)	11 (27.5)	0.35
CKD	16 (19.3)	9 (20.9)	7 (17.5)	0.91
Solid malignancy	24 (28.9)	14 (32.6)	10 (25)	0.61
Hematological malignancy	14 (16.9)	4 (9.3)	10 (25)	0.11
Recipient of solid organ transplantation	21 (25.3)	11 (25.6)	10 (25)	1
HSCT	7 (8.43)	3 (6.98)	4 (10)	0.71
HIV/AIDS	1 (1.2)	0 (0)	1 (2.5)	0.48
Hypertension	24 (28.9)	11 (25.6)	13 (32.5)	0.65
Neuromuscular blockers post-randomization, N (%)	7 (8.43)	2 (4.65)	5 (12.5)	0.25
SOFA score	8 (5-10)	8 (6-9)	8 (5-10)	0.87
APACHE II	20 (13-26)	19 (14-25)	20.5 (13-26.75)	0.83
Lactate at baseline, mmol/L	1.8 (1.2-3.05)	1.4 (1-2.3)	2.2 (1.58-3.4)	0.004
PO2/ FiO2 ratio	152 (94.1-294)	144 (88.9-263)	156 (99.2-314)	0.77
PRE-DELIRIC score (%)	20 (12- 33)	20 (12-36)	20 (13-28)	0.68
Heart rate (HR), beats/ min	93 (80-106)	91 (79-105)	93.5 (81.5-106)	0.48
Mean arterial pressure (MAP), mmHg	77 (69-89.5)	77 (69.5-88.5)	76.5 (65.5-91)	0.87

Data presented as n (%), mean ± sd, or median (interquartile range).

Abbreviations: APACHE II, Acute Physiology And Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; HR, heart rate; HIV/AIDS, Human immunodeficiency virus infection and acquired immunodeficiency syndrome; HSCT, hematopoietic stem-cell transplantation; MAP, mean arterial pressure; PaO2, partial pressure of oxygen; SOC, standard of care; SOFA, Sequential Organ Failure Assessment

Table 2. Outcomes

	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
Primary and co-primary outcome				
MV within 28 days post-intubation, N (%)				1
No	52 (62.7)	27 (62.8)	25 (62.5)	
Yes	31 (37.3)	16 (37.2)	15 (37.5)	
28-day duration of MV, days	5 (2-9)	5 (2-8)	7 (3-9.25)	0.15
Duration of MV at ICU discharge/death, days	8 (3-18.5)	7 (3-13.8)	9 (3-19)	0.32
Ventilation-free days, days ^a	19 (0-24)	19 (0-24)	19 (0-24.75)	0.70
Secondary				
Patients at goal RASS at 24 h, N (%) ^b	49 (59.8)	22 (52.4)	27 (67.5)	0.24
Patients at goal RASS at 48 h, N (%) ^c	51 (69.9)	26 (66.7)	25 (73.5)	0.70
Patients at Goal pain score at 24 h, N (%) ^a	80 (96.39)	41 (95.35)	39 (97.5)	1
Patients at Goal pain score at 48 h, N (%) ^a	79 (95.2)	41 (95.3)	38 (95)	1
Discharge from ICU, N (%)	76 (91.6)	40 (93)	36 (90)	0.71
ICU length of stay, days	12 (6-22.5)	12 (5.5-23)	12.5 (6-21.2)	0.89
Disposition at ICU discharge, N (%)				0.64
Morgue	28 (33.7)	16 (37.2)	12 (30)	
Floor	55 (66.3)	27 (62.8)	28 (70)	
Hospital discharge, N (%)	79 (95.2)	41 (95.3)	38 (95)	1
Hospital length of stay, days	26 (13-39)	27 (12.5-47)	26 (15.8-38)	0.87
Disposition at hospital discharge, N (%)				0.96
Home	41 (49.4)	21 (48.8)	20 (50)	
Morgue	38 (45.8)	20 (46.5)	18 (45)	
Another facility	1 (1.2)	1 (2.33)	0 (0)	
Still in hospital	3 (3.61)	1 (2.33)	2 (5)	

Data presented as n (%), mean ± sd, or median (interquartile range).

^a 53 patients (26 SOC and 27 ketamine) were alive and zero VFD was assigned for patients who died within 28 days

^b The RASS measures levels of consciousness (scores range from -5 [unresponsive] to +4 [combative]). Assessed in 82 patients at

24 hours (42 SOC and 40 ketamine-treated)

^c The RASS was assessed in 73 patients at 48 hours (39 SOC and 34 in ketamine-treated)

^d Assessment of pain was done by Critical Care Pain Observation Tool for pain (CPOT)

Abbreviations: MV, mechanical ventilation; RASS, Richmond Agitation and Sedation; SOC, standard of care

Table 4. Safety outcomes

	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
28-day Tracheotomy, N (%)	22 (26.5)	11 (25.6)	11 (27.5)	1
28-day unplanned extubation/Self-extubation, N (%)	2 (2.41)	0 (0)	2 (5)	0.23
Patients who did not complete 48h of trial, N (%)	20 (24.1)	5 (11.63)	15 (37.5)	0.01
Reason for trial discontinuation before 48h, N (%)				
Excessive sedation and patients not in target RASS	2 (10)	0 (0)	2 (13.3)	1
Death	4 (20)	2 (40)	2 (13.3)	0.25
Goal changed to comfort care	2 (10)	1(20)	1 (6.67)	0.45
Extubation and weaning off sedation in 48h	14 (70)	3 (60)	11 (73.33)	0.61
Physician decline patient participation	1 (5)	0 (0)	1 (6.67)	1
Hemodynamics				
HR at 24h	92 (75.5-107)	95 (80-107)	83.5 (71.8-105)	0.11
HR at 48h	84 (72-100)	89 (75 - 104)	82 (71- 99)	0.31
MAP at 24h	75 (64.5-87)	75 (62.5 - 86.5)	74.5 (69.5- 91.5)	0.31
MAP at 48h	77 (65-90)	76 (67.5-87)	77.5 (64-92.5)	0.50
Uncontrolled agitation, N (%)	10 (12.05)	4 (9.3)	6 (15)	0.51
Combative behavior to the nursing staff, N (%)	2 (2.41)	1 (2.33)	1 (2.5)	1
Hyper-salivation and frequent suctioning, N (%)	22 (26.5)	14 (32.6)	8 (20)	0.29
Patient started on antipsychotics within 48h post- randomization, N (%)	7 (8.43)	4 (9.3)	3 (7.5)	1
Use of physical restraint 48h post-randomization, N (%)	22 (26.5)	10 (23.3)	12 (30)	0.66
28-day mortality rate, N (%)	25 (30.1)	14 (32.6)	11 (27.5)	0.79

Data presented as n (%), mean ± sd, or median (interquartile range).

Abbreviations: CAM-ICU, Confusion Assessment Method for the ICU; HR, heart rate; MAP, mean arterial pressure; RASS,

Richmond Agitation and Sedation Scale; SOC, standard of care.

Supplementary Data

Table of Content :

- 1- Supplementary Table 1: Full inclusion and exclusion criteria
- 2- Supplementary Figure 1A: Treatment algorithm for patient randomized to standard of care Supplementary Figure 1B: Treatment algorithm for patient randomized to ketamine
- 3- Supplementary file 1: CRFs used for screening and data collection in Research Electronic Data Capture (REDCap)- submitted separately
- 4- Supplementary Table 2: Details of outcome variables definition
- 5- Supplementary Table 3. Other demographic and baseline characteristics
- 6- Supplementary Figure 2: Time-to-event and Kaplan-Maier Curves
- 7- Supplementary Table 4: Cox-proportional regression analysis for weaning off mechanical ventilation
- 8- Supplementary Table 5: Other safety outcomes
- 9- Supplementary Table 6: Sedatives and vasopressors requirements
- 10-Supplementary Figure 3: Box plots for cumulative doses of sedatives at 48 hours' postrandomization
- 11-Supplementary Figure 4: Box plots for cumulative doses of vasopressors at 48 hours' postrandomization
- 12-Supplementary Table 7: Sensitivity analysis for sedatives and vasopressors requirements excluding patients started on atracurium post-randomization

Supplementary Table 1: Full inclusion and exclusion criteria

Inclusion criteria:

- 1. Adults patients (>14 years)
- 2. Recently intubated and commenced on mechanical ventilation within the last 24 hours.
- 3. Admitted to one of the following ICUs (Medical, Surgical, transplant/oncology or COVID-19).
- 4. Expected to require MV longer than 24 hours.
- 5. Expected to be on the KFSH&RC sedation protocol.
- 6. There is no objection of the ICU attending for enrollment.

Patients with the above inclusion criteria and has one of the following exclusion criteria were screened then excluded:

- Patients with a history of dementia or psychiatric disorders or those on any antipsychotic or antidepressant medications at home.
- Pregnancy.
- Age < 14 years old.
- Expected to need MV < 24 h.
- Known hypersensitivity to ketamine.
- Patients with expected targeted RASS score of 5, e.g., patients on continuous infusion neuromuscular blockade.
- Patients on dexmedetomidine as the primary sedative prior to randomization.
- Patients with cardiogenic shock, acute decompensated heart failure, or myocardial infarction
- History of end-stage liver failure (Child-Pugh score C).
- Proven or suspected primary neurological injury (traumatic brain injury, ischemic stroke, intracranial hemorrhage, spinal cord injury, anoxic brain injury, brain edema).
- Patients with persistent heart rate (HR) > 150 beats per minute (bpm) or systolic blood pressure (SBP)
 >180mmHg.
- Patients identified as Do Not Resuscitate (DNR) or those expected to die within 24 h.
- Patients on extracorporeal membrane oxygenation (ECMO).
- Patients with refractory status epilepticus who are receiving ketamine infusion.
- Proven or suspected status asthmaticus (the dose of this indication differed from the recommended dose for analgosedation)

Supplementary Figure 1A: Treatment algorithm for Patient Randomized to Standard of care



Supplementary Figure 1B: Treatment algorithm for Patient Randomized to Ketamine



ketamine

Supplementary Table 2: Details of outcome variables definition

Severity of illness	 Estimated by Sequential Organ Failure Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation (APACHE II) score, with higher scores indicating higher severity of illness The Sequential Organ Failure Assessment (SOFA) is used to track organ failure in the ICU; scores range from 0 to 24, with higher scores indicating greater severity of illness The Acute Physiology and Chronic Health Evaluation (APACHE II) assesses the risk of death on a scale from 0 to 71, with higher scores indicating a higher risk of death.
PRE-DELIRIC Delirium Risk Score	• A delirium prediction model specifically designed for adult critical care patients 24 h after ICU admission. This model was used to predict the factors that may influence delirium risk prior to randomization
Duration of MV	 Was recorded as either the number of calendar days from intubation to extubation or until ICU discharge or death, whichever occurred first. This outcome was chosen as a patient-centered outcome and based on the mechanistic plausibility data that showed ketamine possibly has a bronchodilatory effect and maintains respiratory drive and airway reflexes
Successful extubation	Was defined as the absence of the need for reintubation within 48 hours.
Cumulative dose of pain and sedatives	 Reported as proportion and median dose in the first 48 h after randomization
Patients achieving the RASS goal and pain score goal	 Reported as proportion of patients achieving this goal within the first 24 and 48 h after Randomization The RASS is a scale used to assess the depth of sedation on a scale of - 5 to + 4, with a negative value indicating deeper sedation and positive values indicating increased agitation Assessment of pain was done by Critical Care Pain Observation Tool for pain (CPOT) by evaluating facial expression, body movement, muscle tension, and adherence to use of the ventilator if intubated or vocalization if extubated. Total scores range from 0 to 8, with scores higher than 2 indicating the presence of pain.
vasopressor requirements	 Reported as proportion and median vasopressor requirements in the first 48 h after randomization
ICU and hospital LOS	 Number of calendar days (median, IQR) from randomization to discharge date from the ICU or hospital

Mortality rate	• Reported as proportion at the time of hospital discharge or 28 days after randomization,
	whichever comes first
Adverse events	• Any clinically significant worsening in a study participant's condition based on clinical judgment compared to the baseline status at the time of randomization will be recorded as an AE. This is applied whether or not the AE is considered to be related to the study treatment.
	• Tachycardia was defined as a heart rate > 130 beats per minute
	 Hyper or hypotension was classified as systolic blood pressure ≥ 180 mmHg and ≤ 90 mmHg, respectively
	• Tracheostomy, unplanned extubation (self-extubation), and re-intubation Reported as proportion of patients within 28 days post-randomization
	• Hypersalivation: defined as frequent suctioning the first 48 h after randomization (defined as interval between suctioning episodes 2 h or less). We calculated the modified Clinical Pulmonary Infection Score (CPIS) to differentiate secretions caused by patients' underlying lung pathology (ventilator-associated pneumonia [VAP]) vs ketamine-associated hypersalivation
	Physical restraint was reported as proportion of patients within 48 h after randomization
	• The incidence of delirium was reported as proportion of patients starting on antipsychotics and positive CAM-ICU score to assess the incidence of delirium 48 h after randomization. The presence of delirium will also be confirmed through a psychiatrist consultation
	• We believe the administration of sedative agents is standard of practice in the ICU to minimize a patient's discomfort while on MV. Hence, the expected adverse effects will not exceed what is encountered during daily practice (e.g., benzodiazepine-associated delirium, opioid-induced constipation, hemodynamic instability associated with propofol and dexmedetomidine, ketamine-associated sympathetic stimulation "tachycardia and increase in blood pressure," and possible delirium).
Serious adverse events	 Included death or potentially life-threatening adverse effects that requires inpatient hospitalization or prolongation of hospitalization, or results in permanent or significant disability/incapacity, congenital anomaly/birth defect, or the investigator considers significant.
	• An independent Research Advisory Council at our institution served as a Data Safety Monitoring Committee (DSMC) and reviewed all adverse events (including all deaths). This committee included faculty with expertise in various disciplines engaged in human subjects' research from the hospital and research centre, and also community members. Consultants with special expertise might be invited to assist from time to time with complex issues. The committee will undertake periodic reviews at the discretion of the Chair, and an expedited review is done for all serious unexpected adverse events (SUAEs). The committee has the authority to suspend or halt recruitment if necessary.
	• No formal interim analysis of efficacy will be undertaken due to possible small numbers that might preclude determination of a statistically significant difference in outcomes between the arms. No stopping rules is specified.

Supplementary Table 3. Other demographic and baseline characteristics

	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
Other primary reason for ICU admission, N (%)				
Metabolic and endocrine disorder	1 (1.2)	1 (2.33)	0 (0)	1
Renal	6 (7.23)	3 (6.98)	3 (7.5)	1
Hematological	3 (3.61)	1 (2.33)	2 (5)	0.61
Major surgery	25 (30.1)	11 (25.6)	14 (35)	0.49
Source of infection, N (%)				
Gastrointestinal	5 (6.02)	2 (4.65)	3 (7.5)	0.67
Urine	6 (7.23)	4 (9.3)	2 (5)	0.68
Blood	9 (10.8)	3 (6.98)	6 (15)	0.30
Skin and soft tissue infections and osteomyelitis	2 (2.41)	2 (4.65)	0 (0)	0.49
Respiratory	26 (31.3)	13 (30.2)	13 (32.5)	1
Unknown	11 (13.3)	4 (9.3)	7 (17.5)	0.44
Renal replacement therapy at baseline, N (%)	7 (8.43)	3 (6.98)	4 (10)	0.71
Type of RRT, N (%)				1
iHD	5 (71.4)	2 (66.7)	3 (75)	
CVVH	1 (14.3)	1 (33.3)	0 (0)	
CVVHDF	1 (14.3)	0 (0)	1 (25)	
Urea at baseline, mmol/L	7.2 (4.25-14.4)	7.7 (4.65-17.6)	6.15 (4.12-10.9)	0.27
Mode of mechanical ventilation, N (%)				0.08
AC	43 (51.8)	19 (44.2)	24 (60)	
PCV	19 (22.9)	14 (32.6)	5 (12.5)	
PS	1 (1.2)	1 (2.33)	0 (0)	
SIMV	1 (1.20)	1 (2.33)	0 (0)	
PRVC	19 (22.9)	8 (18.6)	11 (27.5)	
PH from ABG	7.31 (7.24-7.40)	7.34 (7.25-7.42)	7.3 (7.23-7.37)	0.31
PCO2 from ABG, kilopascals	6 (5-7.5)	6 (5.1-7.6)	5.9 (4.97-7.34)	0.56
PO2 from ABG, kilopascals	10.5 (7.45-14.1)	10.6 (6.85-14.1)	10.1 (8.15-14.2)	0.79
HCO3 from ABG, mmol/L	23.6 (20.1-29.2)	23.7 (20.4-31.3)	23.3 (19.5-27.5)	0.31
Metabolic acidosis, N (%)	29 (34.9)	15 (34.9)	14 (35)	1
FiO2	0.5 (0.35-0.7)	0.5 (0.4-0.7)	0.5 (0.34-0.82)	0.66

Abbreviations: AC, assist-control mode; ABG, arterial blood gas; CKD, chronic kidney disease; CVVH, continuous veno-venous hemofiltration; FiO2, fraction of inspired oxygen; IHD, intermittent hemodialysis; RRT, renal replacement therapy; PaO2, partial pressure of oxygen; PCO2, partial pressure of carbon dioxide; PCV, pressure control ventilation; PS, pressure support; PRVC, pressure-regulated volume control; SIMV, Synchronized intermittent mandatory ventilation

Supplementary Figure 2: Time-to-event and Kaplan-Maier Curves

Kaplan-Meier curve with a corresponding log-rank test was used to estimate the probability of weaningoff MV. Patients who were not weaned-off MV during their ICU stay were censored at the last follow-up date. Kaplan-Maier estimates with a corresponding log-rank test were also used to compare the survival probability, hospital and ICU LOS between patients who received ketamine and patients who did not. Patients who alive or stayed in the ICU were censored at the last follow-up date.





Panel B.



Panel C.

Panel D.

Figure caption: Panel A for duration of mechanical ventilation; Panel B represents the overall ICU length of stay (days); Panel C represents the overall hospital length of stay (days); Panel D represents 28-day mortality. Red line represents the standard of care group and blue line represents the ketamine group. Confidence interval was illustrated as a band around the time-to-event curves. SOC donates to standard of care

Supplementary	Table	4:	Cox-proportional	regression	analysis	for	weaning	off	mechanical
ventilation									

Predictors	HR	95% CI	p
Age	0.99	0.97 – 1.01	0.352
APACHE II on admission	0.99	0.94 - 1.03	0.620
SOFA score	0.97	0.87 – 1.08	0.536
Urea at baseline (mmol/L)	1.02	0.99 – 1.04	0.235
ketamine: No	Reference		
ketamine: Yes	1.19	0.66 - 2.16	0.563
Metabolic acidosis: No	Reference		
Metabolic acidosis: Yes	0.48	0.24 – 0.94	0.032
ICU type: Medical	Reference		
ICU type: Surgical	2.09	1.06 - 4.14	0.034
ICU type: transplant	2.11	1.02 – 4.35	0.043

Table legend: Abbreviation: APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA,

Sequential Organ Failure Assessment; HR : hazard ratio; CI: confidence interval

Cox-proportional regression analysis was used to assess factors associated with probability for weaning off MV and was reported as hazard ratio (HR) and 95% confidence interval (CI). The adjustment of observed effects was undertaken using a list of a priori defined covariates [age, Acute Physiology And Chronic Health Evaluation II (APACHE-II) score, Sequential Organ-Failure Assessment (SOFA) score, comorbidities, and ICU type].

The Cox-proportional hazard regression model showed that a lower probability of weaning off MV in patients with metabolic acidosis (HR [95% CI]): 0.48, [0.24-0.94], P = 0.032), whereas ICU admission for surgical reasons and transplant or oncology reasons was associated with a higher probability of weaning off MV [HR (95% CI): 2.09 (1.06–4.14) for surgical ICU, 2.11 (1.02–4.35) for transplant ICU] compared to medical admission

Supplementary Table 5: Other safety outcomes

	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
Persistent tachycardia within the first 48h [HR > 130 beats/minutes] , N (%)	4 (4.82)	1 (2.33)	3 (7.5)	0.35
Persistent hypertension within the first 48h [systolic blood pressure ≥ 180 mmHg] , N (%)	1 (1.2)	0 (0)	1 (2.5)	0.48
CPIS score within 48h post-randomization ^a	4 (2-5)	4 (3-6)	3.5 (2-4.25)	0.02
Pneumonia , N (%)	16 (19.3)	10 (23.3)	6 (15)	0.41
Patient started on antipsychotics within 48h post- randomization, N (%)	7 (8.43)	4 (9.3)	3 (7.5)	1
Haldol	1 (14.3)	1 (25)	0 (0)	1
Quetiapine	5 (71.4)	2 (50)	3 (100)	0.43
Risperidone	1 (14.3)	1 (25)	0 (0)	1
Olanzapine	1 (14.3)	0 (0)	1 (33.3)	0.43
Psychiatric Physician consulted, N (%)	1 (1.20)	0 (0)	1 (2.5)	0.48
Cause of death, N (%)				
Cardiogenic shock	4 (17.4)	3 (23.1)	1 (10)	0.60
Septic shock	15 (62.5)	9 (64.3)	6 (60)	1
Hypovolemic shock	4 (17.4)	3 (23.1)	1 (10)	0.60
Respiratory	17 (68)	8 (57.1)	9 (81.8)	0.23
Metabolic	6 (26.1)	4 (30.8)	2 (20)	0.66
Multi-organ failure	16 (66.7)	11 (78.6)	5 (50)	0.20

Data presented as n (%), mean ± sd, or median (interquartile range). SOC donates to standard of care

^{*a*} CPIS score was used to differentiate secretions caused by patients' underlying lung pathology (ventilator- associated pneumonia [VAP]) vs ketamine-associated hypersalivation. Likelihood of VAP does seem to be somewhat higher when scores are >6 **Abbreviations**: CPIS, Clinical Pulmonary Infection Score

		Baseline	±			48h post-random	nization	
	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
RASS Score ^{<i>a</i>}	-2 (-4 to -1)	-2 (-4 to -1)	-2.50 (-4 to -0.25)	0.76	-1 (-3 to -1)	-1.50 (-3 to -1)	-1.00 (-3 to 0)	0.85
pain score ^b	0 (0-0)	0 (0-0)	0 (0-0)	0.60	0 (0-0)	0 (0-0)	0 (0-0)	0.31
CAM-ICU Positive, N (%) ^c	1 (1.2)	0 (0)	1 (2.5)		2 (2.41)	0 (0)	2 (5)	
CAM-ICU Negative, N (%) ^c	36 (43.37)	19 (44.19)	17 (42.5)	0.58	34 (40.96)	19 (44.19)	15 (37.5)	0.30
CAM-ICU Not assessed, N (%) ^c	46 (55.42)	24 (55.81)	22 (55)		47 (56.63)	24 (55.81)	23 (57.5)	
Fentanyl, N (%)	80 (96.4)	40 (93.0)	40 (100)	0.24	82 (98.8)	43 (100)	39 (97.5)	0.48
Propofol, N (%)	70 (84.3)	35 (81.4)	35 (87.5)	0.64	48 (57.8)	24 (55.8)	24 (60)	0.87
Midazolam, N (%)	47 (56.6)	24 (55.8)	23 (57.5)	1	14 (16.9)	8 (18.6)	6 (15)	0.89
Dexmedetomidine, N (%)					16 (19.3)	12 (27.9)	4 (10)	0.05
Cumulative dose of fentanyl (µg)	1475 (681-2600)	1262 (488-2612)	1612 (1100-2512)	0.17	3938 (2100- 6400)	3817 (2220- 6140)	4400 (1588-7700)	0.67
Fentanyl daily dose (µg /Kg)	23.4 (9.9 - 39.7)	21 (7.37-37.2)	26.4 (15.7-43.2)	0.22	66.8 (26.6-105)	63.5 (32.8-97.1)	69.6 (22.7-110)	0.69
Cumulative dose of propofol (mg)	755 (172-1738)	780 (150-1425)	640 (215-1850)	0.37	1990 (530-3862)	2091 (492-3316)	1815 (778-4272)	0.95
Propofol daily dose (mg/Kg)	10.9 (3.26-24.7)	12.7 (2.13-22.2)	10.6 (4.38-25.3)	0.63	28.4 (9.29-59)	28.4 (6.59-58.1)	28 (9.62-60.9)	1
Cumulative dose midazolam (mg)	5 (3 -5.75)	4.75 (2-5.38)	5 (3 - 6)	0.54	12.5 (5.25-101)	7 (4.5 -32.2)	62.8 (17.1-125)	0.11
Midazolam daily dose (mg/Kg)	0.08 (0.04-0.13)	0.08 (0.04-0.13)	0.08 (0.05-0.12)	0.89	0.24 (0.1 -1.25)	0.15 (0.08-0.49)	0.85 (0.26-1.74)	0.16

	Baseline			48h post-randomization				
	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р	All (N=83)	SOC (N=43)	Ketamine (N=40)	Р
Cumulative Dexmedetomidine dose (µg)					667 (357-1222)	667 (357-1222)	711 (310-1730)	0.90
Dexmedetomidine Daily dose (μg /Kg)		•	•		9.34 (5.33-22.8)	9.34 (5.33-22)	18 (4.67-35.5)	0.63
Norepinephrine, N (%)	50 (60.2)	26 (60.5)	24 (60)	1	52 (62.7)	27 (62.8)	25 (62.5)	1
Epinephrine, N (%)	6 (7.23)	4 (9.3)	2 (5)	0.68	5 (6.02)	1 (2.33)	4 (10)	0.19
Phenylephrine, N (%)	24 (28.9)	16 (37.2)	8 (20)	0.14	11 (13.3)	5 (11.6)	6 (15)	0.89
Vasopressin, N (%)	8 (9.64)	5 (11.6)	3 (7.5)	0.71	15 (18.1)	8 (18.6)	7 (17.5)	1
Dopamine, N (%)	4 (4.82)	2 (4.65)	2 (5)	1	5 (6.02)	3 (6.98)	2 (5)	1
Cumulative dose of Norepinephrine (mg)	5.92 (2.5-12.1)	5.92 (1.82-10.7)	6.35 (3.53-14.2)	0.38	9 (4.92-28)	8.63 (6.13-26)	9.37 (4.4-28.4)	0.89
Cumulative dose of epinephrine (mg)	1.17 (0.43-1.37)	1.24 (0.53-1.5)	0.81 (0.47-1.15)	0.36	6.09 (2-13.1)	29.2 (29.2-29.2)	4.04 (1.88-7.84)	0.16
Cumulative phenylephrine dose (mg)	0.45 (0.3-1.1)	0.45 (0.3-1.3)	0.45 (0.3-0.7)	0.78	0.60 (0.21- 46.8)	36 (0.5-57.6)	0.45 (0.17-5.1)	0.52
Cumulative dose of dopamine (mg)	133 (70.6 -203)	133 (110-156)	149 (86.2- 213)	1	563 (490-676)	563 (482-619)	602 (546-659)	0.56
Cumulative vasopressin (units)	18.2 (11.4-27.9)	12 (9.6-15)	39.6 (30.5-64.2)	0.05	70.8 (30-91.6)	24 (21.6 - 82.8)	81.6 (60 - 89.6)	0.20

Data presented as n (%), mean ± sd, or median (interquartile range). SOC donates to standard of care

^a The RASS measures levels of consciousness (scores range from -5 [unresponsive] to +4 [combative]])

^b Assessment of pain was done by Critical Care Pain Observation Tool for pain (CPOT)

^c The CAM-ICU, scores delirium as either present [positive] or not present [negative]). Assessments were done when the patient was maximally awake. if in coma, unable to evaluate.

Abbreviation: CAM-ICU, Confusion Assessment Method for the ICU; RASS, Richmond Agitation and Sedation Scale.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.26.21256072; this version posted June 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Supplementary Figure 3: Box plots for cumulative doses of sedatives at 48 hours' post-randomization



Supplementary Figure 4: Box plots for cumulative doses of vasopressors at 48 hours' postrandomization



SOC donates to standard of care

Supplementary Table 7 Sensitivity analysis for sedatives and vasopressors requirements excluding

patients started on atracurium post-randomization

	SOC (N=41)	Ketamine (N=35)	Р
Patient on fentanyl within 48h, N (%)	41 (100)	34 (97.1)	0.46
Fentanyl route of administration (48h) , N (%)			0.33
Infusion	35 (85.4)	30 (88.2)	
PRN bolus	3 (7.32)	0 (0)	
Both	3 (7.32)	4 (11.8)	
Cumulative dose of fentanyl (mcg) 48h post-randomization	3817 (2200-5900)	3400 (1500-6298)	0.87
Daily dose of fentanyl (mcg/Kg) 48h post-randomization	66.1 (32.7-103)	61.4 (19.5-108)	0.91
Patient on propofol 48h post-randomization, N (%)	22 (53.7)	20 (57.1)	0.94
Propofol route of administration (48h), N (%)			0.09
Infusion	22 (100)	17 (85)	
PRN bolus	0 (0)	1 (5)	
Both	0 (0)	2 (10)	
Cumulative propofol dose (mg) 48h post-randomization	2161 (398-3406)	1688 (778-4272)	0.88
Propofol daily dose (mg/kg) 48h post-randomization	33.6 (7.65-58.5)	27.8 (9.62-56.7)	0.76
Patient on midazolam within 48h post-randomization, N (%)	7 (17.1)	4 (11.4)	0.71
Midazolam route of administration (48h), N (%)			0.49
Infusion	3 (42.9)	1 (25)	
PRN bolus	4 (57.1)	2 (50)	
Both	0 (0)	1 (25)	
Cumulative dose of midazolam (mg) 48h post-randomization	6 (4- 54.5)	58.5 (12.5-110)	0.29
Midazolam daily dose (mg/kg) 48h post-randomization	0.21 (0.09-0.72)	0.74 (0.19-1.43)	0.45
Dexmedetomidine starter within 24h post-randomization, N (%)	12 (29.3)	4 (11.4)	0.11
Cumulative dose of Dexmedetomidine (mcg) 48 post- randomization	667 (357-1222)	711 (310-1730)	0.90

medRxiv preprint doi: https://doi.org/10.1101/2021.04.26.21256072; this ve (which was not certified by peer review) is the author/funder, who has It is made available under a CC-BY-NC-	rsion posted June 5, 2021. granted medRxiv a license t	The copyright holder for this o display the preprint in perp	preprint betuity.
Daily dose of Dexmedetomidine (mcg/Kg) 48h post- randomization	9.34 (5.33-22)	18 (4.67- 35.5)	0.63
Patient on Norepinephrine within 48 h, N (%)	25 (60.89)	21 (60.0)	1
Cumulative dose of Norepinephrine (mg) 48h post- randomization	8.07 (5.27 - 20.07)	8.21 (3.66-28)	0.97
Patient of epinephrine within 48h post-randomization, N (%)	1 (2.44)	2 (5.71)	0.59
Cumulative dose of epinephrine (mg) 48h post- randomization	29.2 (29.2- 29.2)	3.805 (1.52 - 6.09)	0.22
Patient on phenylephrine within 48h post-randomization, N (%)	5 (12.2)	5 (14.29)	1
Cumulative dose of phenylephrine (mg) 48h post- randomization	36 (0.3-72.55)	0.6 (0.213-81.3)	0.75
Patient on dopamine within 48h post-randomization, N (%)	3 (7.32)	2 (5.71)	1
Cumulative dose of dopamine (mg) 48h post-randomization	562.56 (401.74 - 675.84)	602.3 (489.6- 715)	0.56
Patient on vasopressin within 48h post-randomization, N (%)	7 (17.07)	5 (14.29)	1
Cumulative dose of vasopressin (units) 48h post- randomization	48 (21.6 - 95.57)	69.6 (49.2-104.4)	0.41

Data presented as n (%), mean ± sd, or median (interquartile range). SOC donates to standard of care